Who
Peter Cicala
Director
Company insider
Files Form 4 as: Director, Ernexa Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 26 Apr 2024
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,943 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,083 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,943 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,083 at $0.00 | filing |
| 7 Feb 2025filed 10 Feb 2025 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,485 at $0.00 | filing |
| 26 Apr 2024filed 29 Apr 2024 | ERNA Ernexa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,946 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.